{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-074025","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-06-15T20:05:42+00:00","discovered_at":"2026-06-15T20:07:00.269149+00:00","generated_at":"2026-06-15T20:15:51.007854+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Milestone Pharma shareholders approve 6.8M share increase to equity plan","bullets":["Shareholders approved 2019 Equity Plan amendment to increase authorized shares by 6,800,000.","All seven director nominees elected; votes for ranged from 23.4M to 24.2M.","Ratification of PricewaterhouseCoopers as auditor: 75,025,285 for, 249,836 against.","Advisory vote on executive compensation passed: 19,665,705 for, 6,990,920 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-074025","json":"https://secwatch.observer/filing/0001104659-26-074025.json","markdown":"https://secwatch.observer/filing/0001104659-26-074025.md","text":"https://secwatch.observer/filing/0001104659-26-074025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/0001104659-26-074025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/tm2617859d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:15:51.007854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23ca5e9d1fb058b97d52722618d7bd4475e46a89","claim":"Milestone Pharmaceuticals Inc. shareholders approved Election of Directors.","evidence_excerpt":"Proposal 1. Election of Directors The Company’s shareholders elected the nominees below to the Company’s board of directors (the “ Board ”), each to hold office until the Company’s 2027 annual meeting of shareholders (the “ 2027 Annual Meeting ”), or until their successors are duly elected or appointed or until such directors’ earlier resignation or removal. The votes regarding the election of directors were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Joseph Oliveto 23,968,376 3,390,500 48,581,157 Stuart M. Duty 24,188,870 3,170,005 48,581,158 Seth H.Z. Fischer 24,199,513 3,159,363 48,581,157 Lisa M. Giles 24,212,031 3,146,845 48,581,157 Joseph C. Papa 23,437,235 3,921,639 48,581,159 Andrew R. Saik 24,111,218 3,247,657 48,581,158 Michael Tomsicek 24,205,006 3,153,870 48,581,157 Robert J. Wills 23,506,189 3,852,686 48,581,158","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/0001104659-26-074025-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"38a05037bd9f964b76ad78edfb225afd7e9b0c14","claim":"Milestone Pharmaceuticals Inc. shareholders approved 2019 Equity Plan Amendment.","evidence_excerpt":"Proposal 3. 2019 Equity Plan Amendment Proposal 3 was a proposal to approve the 2019 EIP, as amended, to, among other things, increase the number of ordinary shares authorized for issuance by 6,800,000 shares. The votes regarding the 2019 EIP were as follows: Votes For Votes Against Abstentions Broker Non-Votes 19,262,773 5,479,043 2,617,059 48,581,158","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/0001104659-26-074025-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"519439f14b7e8adca618deefcdf281ca09957606","claim":"Milestone Pharmaceuticals Inc. shareholders approved Advisory Vote on Executive Compensation.","evidence_excerpt":"Proposal 4. Advisory Vote on Executive Compensation Proposal 4 was a proposal for a non-binding advisory vote on the compensation of the Company’s named executive officers. The votes regarding the non-binding advisory vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 19,665,705 6,990,920 702,247 48,581,161","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/0001104659-26-074025-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"f3c3278ddaf438b35a71ccf9f323c2babbc4cb70","claim":"Milestone Pharmaceuticals Inc. shareholders approved Appointment of the Auditor.","evidence_excerpt":"Proposal 2. Appointment of the Auditor Proposal 2 was a proposal to ratify the selection by the Company’s Audit Committee of PricewaterhouseCoopers LLP as the auditor for the Company until the close of the 2027 Annual Meeting and the authorization of the Board to fix the auditor’s remuneration. The votes regarding the ratification of the selection of the Company’s auditor were as follows: Votes For Votes Against Abstentions 75,025,285 249,836 664,912","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926074025/0001104659-26-074025-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}